

Cancer Detection Should Be Early, Precise, and Personalized: But How?

Manfred Doepp

Holistic Center, 13 Haupt St., Abtwil 9030, Switzerland

www.drdoepp.org

Editorial

Every cancer patient and every tumor is unique. Early detection is one of the most important factors in improving cancer outcomes. The usual early detection methods take place too late, are time-consuming and expensive. Principally a liquid biopsy in blood concerning circulating tumor cells should be a much better possibility. Through a variety of tests to personalize cancer care, the company RGCC (Research Genetic Cancer Center, <https://rgcc-international.com/>) aims to empower cancer patients with tailored insights that can change the course of their journey.

RGCC applies precision medicine through advanced liquid biopsy testing, analyzing circulating tumor cells and associated biomarkers in the bloodstream. This approach reveals the genetic characteristics of a patient's cancer and supports the development of individualized treatment approaches. RGCC scientists developed «Onco-D-Clare», an advanced cancer screening blood test designed to identify early biological changes linked to cancer

development, based on each individual's genetic profile, before symptoms appear.

The technology behind Onco-D-Clare combines molecular biology with artificial neural networks, integrating gene expression analysis with advanced machine learning algorithms to support early cancer risk assessment. The test is supported by scientific evidence demonstrating that gene-expression profiling can distinguish between normal and cancer-related samples.

For more than 20 years, RGCC has specialized in personalized cancer care. The extensive experience in liquid biopsy testing and analysis of circulating tumor cells, supported by state-of-the-art technologies, provides healthcare professionals with reliable and comprehensive insights into each patient's genetics, physiology, and immune profile.

Concerning therapeutic efficacy

Tests create personalized patient profiles to guide targeted cancer treatments. Many of the existing therapy agents are tested, chemical as well as natural ones. Hence: what are benefits of this tests: 1) Circulating cancer cells yes/no; 2) If yes, what is the

amount? 3) Which cancer type may it be? 4) What well as natural ones?
are the most effective therapy agents, chemical as

Citation of this Article

Doepf M. Cancer Detection Should Be Early, Precise, and Personalized: But How?. *Mega J Case Rep.* 2026;9(5):2001-2002.

Copyright

©2026 Doepf M. This is an Open Access Journal Article Published under [Attribution-Share Alike CC BY-SA](#): Creative Commons Attribution-Share Alike 4.0 International License. With this license, readers can share, distribute, and download, even commercially, as long as the original source is properly cited.